Jonathan Allan sold $138k of STOK
GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc.. 4,576 shares at an average of $30.22, traded Dec 2, 2025, filed Dec 3, 2025.
Score components
- +15RoleOfficer
- +11Trade size$138k at market
- +5Share of holdings soldSold 19% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001966716-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2025 | MOption exercise Common Stock | +12,357 | $0.00 | $0 | 24,188 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock | -1,416 | $29.56 | $42k | 22,772 | Dec 3, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock | -868 | $30.14 | $26k | 21,904 | Dec 3, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock | -898 | $30.34 | $27k | 21,006 | Dec 3, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock | -1,394 | $30.85 | $43k | 19,612 | Dec 3, 2025 |
| Dec 1, 2025 | MOption exercise Restricted Stock Unitsderivative | -12,357 | $0.00 | $0 | 0 | Dec 3, 2025 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 19Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $313k 9,293 shares | -32% | |
| 34Weak | STOKsell Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $286k 8,895 shares | -24% | |
| 31Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $128k 3,978 shares | -25% | |
| 32Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $433k 13,430 shares | -21% | |
| 19Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $306k 9,803 shares | -38% | |
| 17Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $467k 15,001 shares | -19% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $167k 5,358 shares | -21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.